SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

31 Jan 2024 Evaluate
The revenue for the December 2023 quarter is pegged at Rs. 23585.66 millions, about 21.81% up against Rs. 19362.31 millions recorded during the year-ago period.Handsome Net Profit growth of 95.71% reported above the corresponding previous quarter figure of Rs. 4870.74 millions to Rs. 2488.73 millions.OP of the company witnessed a marginal growth to 6703.40 millions from 4059.01 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 23585.66 19362.31 21.81 71121.22 62550.31 13.70 81271.53 74862.22 8.56
Other Income 672.30 324.04 107.47 1827.84 1203.27 51.91 1627.83 2038.14 -20.13
PBIDT 6703.40 4059.01 65.15 19605.57 14365.46 36.48 18601.64 20418.85 -8.90
Interest 42.58 92.44 -53.94 105.36 268.63 -60.78 277.48 471.21 -41.11
PBDT 6660.82 3966.57 67.92 19500.21 14096.83 38.33 18324.16 19947.64 -8.14
Depreciation 897.30 710.20 26.34 2353.12 2022.81 16.33 2695.80 1233.27 118.59
PBT 5763.52 3256.37 76.99 17147.09 12074.02 42.02 15628.36 18714.37 -16.49
TAX 892.78 767.64 16.30 3454.67 2401.33 43.86 3145.79 4820.13 -34.74
Deferred Tax 148.65 97.23 52.88 395.62 293.91 34.61 229.43 529.79 -56.69
PAT 4870.74 2488.73 95.71 13692.42 9672.69 41.56 12482.57 13894.24 -10.16
Equity 400.59 400.59 0.00 400.59 400.59 0.00 400.59 400.59 0.00
PBIDTM(%) 28.42 20.96 35.58 27.57 22.97 20.03 22.89 27.28 -16.08

Mankind Pharma Share Price

2152.30 29.10 (1.37%)
20-Apr-2026 14:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1235.00
Cipla 1232.60
Zydus Lifesciences 936.50
Lupin 2327.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×